01:14 , Sep 30, 2017 |  BioCentury  |  Product Development

Running interference

Editor’s Note: An earlier version of this story was published in BioCentury on Sept. 25. It has been updated to include reporting about safety and efficacy data that was not included in the original. The...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

ALN-AAT: Development discontinued

Alnylam will discontinue development of ALN-AAT after interim data from a single-blind, U.K. Phase I/II trial in 26 healthy volunteers showed that single subcutaneous doses of ALN-AAT led to transient, asymptomatic and dose-dependent elevations in...
07:00 , Sep 29, 2016 |  BC Extra  |  Clinical News

Alnylam switching to backup AAT molecule after safety signal

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said it will discontinue development of ALN-AAT for alpha-1 antitrypsin (AAT; A1AT ; SERPINA1 ) deficiency-associated liver disease due to a low incidence of elevated liver enzymes observed in a Phase...